[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633258":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":74,"collaborators":11,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":11,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":11,"enrollmentInfo":85,"targetDuration":11,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Samsung Bioepis Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"E303","EXPERIMENTAL",null,[13],"Drug: E303",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","All participants will receive an intravenous (IV) infusion of E303",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Samsung Bioepis","CONTACT","+82-32-728-0114","bioepisinfo@samsung.com",[26,40,49,58,67],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":11},"Research Site","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-111.89903,33.50921,{"lat":38,"lon":37},{"facility":27,"status":28,"city":41,"state":42,"zip":43,"country":32,"countryCode":33,"cosmosGeoPoint":44,"geoPoint":48,"contacts":11},"Fairfax","Virginia","22031",{"type":35,"coordinates":45},[46,47],-77.30637,38.84622,{"lat":47,"lon":46},{"facility":27,"status":28,"city":50,"state":11,"zip":11,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Adelaide","Australia","AU",{"type":35,"coordinates":54},[55,56],138.59863,-34.92866,{"lat":56,"lon":55},{"facility":27,"status":28,"city":59,"state":11,"zip":11,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":66,"contacts":11},"Barcelona","Spain","ES",{"type":35,"coordinates":63},[64,65],2.15899,41.38879,{"lat":65,"lon":64},{"facility":27,"status":28,"city":68,"state":11,"zip":11,"country":60,"countryCode":61,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"Madrid",{"type":35,"coordinates":70},[71,72],-3.70256,40.4165,{"lat":72,"lon":71},{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633258","phase-1-a-trial-to-investigate-the-safety-of-e303-in-participants-with-advanced-refractory-solid-tumors-100633258",false,"NCT07524348","A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors","A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors","Inclusion Criteria:\n\n* Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.\n\nExclusion Criteria:\n\n* Have spinal cord compression or clinically active central nervous system metastases\n* Have leptomeningeal disease\n* Have thromboembolic or clinically significant bleeding events\n* Have significant cardiovascular disease\n* Have an active autoimmune disease","ALL","18 Years",{"count":86,"type":87},149,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors",[93],"Advanced Solid Tumors","2026-06-28",{"date":96,"type":97},"2026-06-30","ACTUAL",{"date":99,"type":97},"2026-03-23",{"date":101,"type":87},"2030-07",{"name":5,"class":6},5]